Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m(2) per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellen...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yan, Pearlly, Frankhouser, David, Murphy, Mark, Tam, Hok-Hei, Rodriguez, Benjamin, Curfman, John, Trimarchi, Michael, Geyer, Susan, Wu, Yue-Zhong, Whitman, Susan P., Metzeler, Klaus, Walker, Alison, Klisovic, Rebecca, Jacob, Samson, Grever, Michael R., Byrd, John C., Bloomfield, Clara D., Garzon, Ramiro, Blum, William, Caligiuri, Michael A., Bundschuh, Ralf, Marcucci, Guido
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2012
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448258/
https://ncbi.nlm.nih.gov/pubmed/22786882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-429175
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы